trending Market Intelligence /marketintelligence/en/news-insights/trending/gBRet7jrj09Cqb_eQuY4JA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US pricing watchdog finds J&J's esketamine depression drug too pricey

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US pricing watchdog finds J&J's esketamine depression drug too pricey

The Institute for Clinical and Economic Review found in a draft report that Johnson & Johnson's ketamine-based drug Spravato, approved in the U.S. earlier in March for patients with depression, did not meet the pricing watchdog's threshold for cost-effectiveness.

Spravato is the brand name for esketamine, which was found in clinical studies to be effective against symptoms of treatment-resistant depression, a condition in about one-third of all patients with major depressive disorder presenting with a high rate of suicide.

Using a benchmark called a quality-adjusted life year, or QALY, the U.S. cost-effectiveness evaluator known as ICER evaluates a drug's cost based on both how long a patient lives and the quality of life therein.

Based on a wholesale acquisition cost of $295 per medication device, ICER reported that Spravato cost about $198,000 per QALY, missing the organization's cost-effectiveness threshold of $150,000.

Despite the cost, ICER found that Spravato produced substantial gains in quality of life for patients, though few patients used the drug longer than five years.

"The results of this analysis should be considered in the context of a lack of evidence surrounding the treatment of [treatment-resistant depression], including the complete lack of comparative evidence of esketamine to other potential therapies (i.e., ketamine) and very limited evidence of the impact of important disease modifiers on clinical outcomes, cost of care, and patient quality of life," ICER wrote in the March 21 draft report.

Analysts predict Spravato could be a blockbuster drug for Johnson & Johnson, making up for losses on older drugs in other classes.

ICER plans to publish a full evidence report for Spravato May 9 and has scheduled a meeting of the Midwest Comparative Effectiveness Public Advisory Council May 23 to discuss the findings.